Emerging therapies and evolving paradigms in cardiovascular pharmacotherapy

Q: What is the clinical evidence from this study?

Study design: Editorial. Population: Cardiovascular diseases (residual risk, post-operative AF, heart failure). Intervention: Cardiovascular pharmacotherapies (e.g., Factor XIa inhibitors, Semaglutide, SGLT2 inhibitors).

Bianca Rocca

doi:10.1093/ehjcvp/pvag053

July 20, 2026European Heart Journal - Cardiovascular PharmacotherapyOpen Access

Emerging therapies and evolving paradigms in cardiovascular pharmacotherapy

View Full Paper

Ask AI

Bookmark

Share

Key result

Novel cardiovascular therapies expand treatment paradigms across cardio-renal-metabolic and thrombotic risk domains.

Figures

Key Points

To review novel advances and clinical evidence across antithrombotic, cardio-renal-metabolic, and heart failure pharmacotherapies addressing residual cardiovascular risk.
Synthesized findings from recent clinical studies and trials evaluating factor XIa inhibitors, risk prediction scores, metabolic agents, and biomarker-guided therapies.
Examined a cohort of 4436 patients with post-operative atrial fibrillation after coronary artery bypass grafting between 2009 and 2020 evaluating the PRECISE-DAPT score.
Analyzed target-trial emulation data from the TriNetX database evaluating semaglutide versus non-GLP-1 receptor agonists over approximately 2 years of follow-up.
Factor XIa inhibition proved effective when added to antiplatelet therapy for secondary prevention of non-cardioembolic stroke, but failed to match apixaban in atrial fibrillation.
The four-item PRECISE-DAPT score displayed moderate discrimination and reasonable calibration for major bleeding during the first post-operative year after CABG, though predictive performance remained modest.
Semaglutide was associated with reduced major adverse cardiovascular and cerebrovascular events driven primarily by fewer incident heart failure events, while SGLT2 inhibitors showed sustained reductions in loop-diuretic requirements.

PICO

P

Population

Cardiovascular diseases (residual risk, post-operative AF, heart failure)

I

Intervention / Comparator

Cardiovascular pharmacotherapies (e.g., Factor XIa inhibitors, Semaglutide, SGLT2 inhibitors)

Limitations

This is an editorial providing a broad overview of multiple separate studies (including RCTs and observational data) and does not present new, fully quantified primary outcome data of its own.

Implication

Reviews novel cardiovascular pharmacotherapies across antithrombotic, metabolic, and heart failure regimens, highlighting evolving targets for residual risk reduction.

Abstract

No abstract yet. The journal hasn't published one we can show.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Bianca Rocca (2026) conducted an editorial in Cardiovascular diseases (residual risk, post-operative AF, heart failure). Cardiovascular pharmacotherapies (e.g., Factor XIa inhibitors, Semaglutide, SGLT2 inhibitors) was evaluated.

synapsesocial.com/papers/6ad115e500741cc3fba7db2f https://doi.org/10.1093/ehjcvp/pvag053

View Full Paper

Ask AI

Bookmark

Share

Emerging therapies and evolving paradigms in cardiovascular pharmacotherapy

Figures

Key Points

PICO

Limitations

Implication

Abstract

Discussion

Cite This Study

Emerging therapies and evolving paradigms in cardiovascular pharmacotherapy

Figures

Key Points

PICO

Limitations

Implication

Abstract

Discussion

Cite This Study

Keep reading

More related papers

More from European Heart Journal - Cardiovascular Pharmacotherapy

Keep reading

More related papers

More from European Heart Journal - Cardiovascular Pharmacotherapy